[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100553959":3},{"organization":4,"armGroups":7,"interventions":22,"overallOfficials":29,"centralContacts":34,"locations":43,"responsibleParty":59,"collaborators":61,"id":71,"slug":72,"hasResults":73,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":28,"eligibilityCriteria":77,"healthyVolunteers":73,"sex":78,"minAge":79,"maxAge":80,"enrollmentInfo":81,"targetDuration":28,"studyType":84,"phases":85,"briefSummary":88,"conditions":89,"keywords":91,"overallStatus":45,"whyStopped":28,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":102},{"fullName":5,"class":6},"Frontera Therapeutics","INDUSTRY",[8,14,18],{"label":9,"type":10,"description":11,"interventionNames":12},"FT003 Dose 1","EXPERIMENTAL","Low dose of FT-003",[13],"Genetic: FT-003",{"label":15,"type":10,"description":16,"interventionNames":17},"FT003 Dose 2","Mid dose of FT-003",[13],{"label":19,"type":10,"description":20,"interventionNames":21},"FT003 Dose 3","High dose of FT-003",[13],[23],{"type":24,"name":25,"description":26,"armGroupLabels":27,"otherNames":28},"GENETIC","FT-003","Administered via intraocular injection.",[9,15,19],null,[30],{"name":31,"affiliation":32,"role":33},"Xiaorong Li, Professor","Tianjin Medical University Eye Hospital","PRINCIPAL_INVESTIGATOR",[35,40],{"name":36,"role":37,"phone":38,"phoneExt":28,"email":39},"Xinyan Li","CONTACT","86-021-58206061","xinyan.li@fronteratherapeutics.com",{"name":41,"role":37,"phone":38,"phoneExt":28,"email":42},"Minghui Xue","minghui.xue@fronteratherapeutics.com",[44],{"facility":32,"status":45,"city":46,"state":47,"zip":48,"country":49,"countryCode":50,"cosmosGeoPoint":51,"geoPoint":56,"contacts":57},"RECRUITING","Tianjin","Tianjin,China","300392","China","CN",{"type":52,"coordinates":53},"Point",[54,55],117.17667,39.14222,{"lat":55,"lon":54},[58],{"name":31,"role":37,"phone":28,"phoneExt":28,"email":28},{"type":60,"investigatorFullName":28,"investigatorTitle":28,"investigatorAffiliation":28,"oldNameTitle":28,"oldOrganization":28},"SPONSOR",[62,64,66,68],{"name":32,"class":63},"OTHER",{"name":65,"class":63},"The First Affiliated Hospital of Soochow University",{"name":67,"class":63},"Peking Union Medical College Hospital",{"name":69,"class":70},"Beijing Hospital","OTHER_GOV","100553959","phase-1-gene-therapyft-003-for-wet-amd-100553959",false,"NCT06492863","Gene Therapy(FT-003) for Wet AMD","A Dose-escalation and Dose-expanded Phase I\u002FII Clinical Study to Evaluate the Safety, and Efficacy of FT-003 in Subjects With Wet AMD","Inclusion Criteria:\n\n* Subjects that are willing and able to follow study procedures;\n* Female or male patients 50-80 years old at the time of signing the ICF;\n* Clinically diagnosed with nAMD;\n* Presence of active CNV\n* The best corrected visual acuity (BCVA) of the studied eye is 24-73 letters;\n\nExclusion Criteria:\n\n* •Presence of any other intraocular diseases other than nAMD in the studied eye that would affect the improvement of visual acuity and require treatment during the study for prevention or treatment of visual loss, as judged by the investigator.","ALL","50 Years","80 Years",{"count":82,"type":83},78,"ESTIMATED","INTERVENTIONAL",[86,87],"PHASE1","PHASE2","The goal of this clinical trial is to evaluate the safety, tolerability and efficacy of disposable vitreous injection of FT-003 in subjects with neovascular age-related Macular Degeneration (nAMD). The study was divided into two phases, Phase 1 dose escalation and Phase II dose expansion.",[90],"Neovascular Age-related Macular Degeneration",[25,92],"nAMD","2024-07-01",{"date":95,"type":96},"2024-07-09","ACTUAL",{"date":98,"type":96},"2023-08-15",{"date":100,"type":83},"2028-10-15",{"name":5,"class":6},1]